Anti-inflammatory nutraceuticals and herbal medicines for the management of metabolic syndrome

George Q. Li; Ka H. Wong; Antony Kam; Xian Zhou; E. Omar; A. Algahtani; Kong M.  Li; V. Razmovski-Naumovski; Kelvin  Chan

doi:10.1201/B12696-28

Anti-inflammatory nutraceuticals and herbal medicines for the management of metabolic syndrome

George Q. Li^*
, Ka H. Wong
, Antony Kam
, Xian Zhou
, E. Omar
, A. Algahtani
, Kong M. Li
, V. Razmovski-Naumovski
, Kelvin Chan

^*Corresponding author for this work

Department of Biosciences and Bioinformatics

Research output: Chapter in Book or Report/Conference proceeding › Chapter › peer-review

Abstract

Metabolic syndrome, previously known as syndrome X and insulin resistance syndrome, refers to a constellation of disorders including central obesity, insulin resistance, glucose intolerance, dyslipidemia, and hypertension. These risk factors have been linked to an increased probability of cardiovascular diseases and type 2 diabetes mellitus. The World Health Organization (WHO) estimates that by 2015, approximately 2.3 billion adults worldwide will be overweight, and more than 700 million adults will be obese (WHO 2006). Additionally, the global prevalence of type 2 diabetes will rise to 336 million by 2030 (International Diabetes Foundation 2009).

Original language	English
Title of host publication	Chronic Inflammation
Publisher	CRC Press
ISBN (Electronic)	9780429109874
DOIs	https://doi.org/10.1201/B12696-28
Publication status	Published - 2012

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1201/B12696-28

Cite this

@inbook{d7e84e995bd34e41b6fe09845480468e,

title = "Anti-inflammatory nutraceuticals and herbal medicines for the management of metabolic syndrome",

abstract = "Metabolic syndrome, previously known as syndrome X and insulin resistance syndrome, refers to a constellation of disorders including central obesity, insulin resistance, glucose intolerance, dyslipidemia, and hypertension. These risk factors have been linked to an increased probability of cardiovascular diseases and type 2 diabetes mellitus. The World Health Organization (WHO) estimates that by 2015, approximately 2.3 billion adults worldwide will be overweight, and more than 700 million adults will be obese (WHO 2006). Additionally, the global prevalence of type 2 diabetes will rise to 336 million by 2030 (International Diabetes Foundation 2009).",

author = "Li, \{George Q.\} and Wong, \{Ka H.\} and Antony Kam and Xian Zhou and E. Omar and A. Algahtani and Li, \{Kong M.\} and V. Razmovski-Naumovski and Kelvin Chan",

year = "2012",

doi = "10.1201/B12696-28",

language = "English",

booktitle = "Chronic Inflammation",

publisher = "CRC Press",

}

TY - CHAP

T1 - Anti-inflammatory nutraceuticals and herbal medicines for the management of metabolic syndrome

AU - Li, George Q.

AU - Wong, Ka H.

AU - Kam, Antony

AU - Zhou, Xian

AU - Omar, E.

AU - Algahtani, A.

AU - Li, Kong M.

AU - Razmovski-Naumovski, V.

AU - Chan, Kelvin

PY - 2012

Y1 - 2012

N2 - Metabolic syndrome, previously known as syndrome X and insulin resistance syndrome, refers to a constellation of disorders including central obesity, insulin resistance, glucose intolerance, dyslipidemia, and hypertension. These risk factors have been linked to an increased probability of cardiovascular diseases and type 2 diabetes mellitus. The World Health Organization (WHO) estimates that by 2015, approximately 2.3 billion adults worldwide will be overweight, and more than 700 million adults will be obese (WHO 2006). Additionally, the global prevalence of type 2 diabetes will rise to 336 million by 2030 (International Diabetes Foundation 2009).

AB - Metabolic syndrome, previously known as syndrome X and insulin resistance syndrome, refers to a constellation of disorders including central obesity, insulin resistance, glucose intolerance, dyslipidemia, and hypertension. These risk factors have been linked to an increased probability of cardiovascular diseases and type 2 diabetes mellitus. The World Health Organization (WHO) estimates that by 2015, approximately 2.3 billion adults worldwide will be overweight, and more than 700 million adults will be obese (WHO 2006). Additionally, the global prevalence of type 2 diabetes will rise to 336 million by 2030 (International Diabetes Foundation 2009).

U2 - 10.1201/B12696-28

DO - 10.1201/B12696-28

M3 - Chapter

BT - Chronic Inflammation

PB - CRC Press

ER -

Anti-inflammatory nutraceuticals and herbal medicines for the management of metabolic syndrome

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this